Nanovaccines to combat virus‐related diseases
Authors:
- 2 October 2022
- journal article
- review article
- Published by Wiley in WIREs Nanomedicine and Nanobiotechnology
- Vol. 15 (2) , e1857
Abstract
The invention and application of vaccines have made tremendous contributions to fight against pandemics for human beings. However, current vaccines still have shortcomings such as insufficient cellular immunity, the lack of cross‐protection, and the risk of antibody‐dependent enhancement (ADE). Thus, the prevention and control of pandemic viruses including Ebola Virus, human immunodeficiency virus (HIV), Influenza A viruses, Zika, and current SARS‐CoV‐2 are still extremely challenging. Nanoparticles with unique physical, chemical, and biological properties, hold promising potentials for the development of ideal vaccines against these viral infections. Moreover, the approval of the first nanoparticle‐based mRNA vaccine BNT162b has established historic milestones that greatly inspired the clinical translation of nanovaccines. Given the safety and extensive application of subunit vaccines, and the rapid rise of mRNA vaccines, this review mainly focuses on these two vaccine strategies and provides an overview of the nanoparticle‐based vaccine delivery platforms to tackle the current and next global health challenges.This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Infectious Disease Therapeutic Approaches and Drug Discovery > Emerging TechnologiesKeywords
Funding Information
- Higher Education Discipline Innovation Project (B18035)
- National Natural Science Foundation of China (81925036)
- Sichuan Veterinary Medicine and Drug Innovation Group of China Agricultural Research System (CARS‐SVDIP)
This publication has 143 references indexed in Scilit:
- Cross-presentation by dendritic cellsNature Reviews Immunology, 2012
- A Double-Inactivated Severe Acute Respiratory Syndrome Coronavirus Vaccine Provides Incomplete Protection in Mice and Induces Increased Eosinophilic Proinflammatory Pulmonary Response upon ChallengeJournal of Virology, 2011
- Programming the magnitude and persistence of antibody responses with innate immunityNature, 2011
- T Cell Responses Are Required for Protection from Clinical Disease and for Virus Clearance in Severe Acute Respiratory Syndrome Coronavirus-Infected MiceJournal of Virology, 2010
- Diffusion of Particles in the Extracellular Matrix: The Effect of Repulsive Electrostatic InteractionsBiophysical Journal, 2010
- Development of a recombinant tetravalent dengue virus vaccine: Immunogenicity and efficacy studies in mice and monkeysVaccine, 2010
- Cellular Immune Responses to Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) Infection in Senescent BALB/c Mice: CD4+T Cells Are Important in Control of SARS-CoV InfectionJournal of Virology, 2010
- Innovative strategies for co-delivering antigens and CpG oligonucleotidesAdvanced Drug Delivery Reviews, 2009
- Virus-Like Particle Vaccine Induces Protective Immunity against Homologous and Heterologous Strains of Influenza VirusJournal of Virology, 2007
- Adjuvant-Enhanced Antibody Responses in the Absence of Toll-Like Receptor SignalingScience, 2006